硝苯地平控释片与缬沙坦联合应用于2型糖尿病肾病并高血压患者中的效果及对CysC、Hcy的影响

The Effect of Nifedipine Controlled-release Tablets and Valsartan in Patients with Type 2 Diabetic Nephropathy and Hypertension and Its Influence on CysC and Hcy

目的探讨硝苯地平控释片与缬沙坦联合应用于2型糖尿病肾病并高血压患者中的效果及对血清膀胱抑素C(CysC)与同型半胱氨酸(Hcy)的影响。方法98例研究对象均为2019年12月—2020年11月该院收治的糖尿病肾病并高血压患者,以随机数表法将其划分为两组。两组患者均接受常规降糖治疗,并严格进行糖尿病饮食,合理运动。对照组口服硝苯地平控释片,研究组在此基础上口服缬沙坦胶囊治疗。比较两组治疗前后血糖[空腹血糖(FPG)、餐后血糖(2 hPG)、糖化血红蛋白(HbA1c)]、血压[收缩压(SBP)与舒张压(DBP)]、肾功能[血肌酐(SCr)、尿素氮(BUN)、24 h尿蛋白排泄率(UAER)]、CysC与Hcy水平,以及不良反应情况。结果治疗后,研究组血糖(FPG、2 hPG、HbA1c)、血压(SBP、DBP)水平较对照组更低,差异有统计学意义(P<0.05),SCr、BUN、UAER水平较对照组更低,差异有统计学意义(P<0.05),CysC与Hcy水平较对照组更低,差异有统计学意义(P<0.05)。两组不良反应发生率对比中,研究组4.08%与对照组4.08%对比差异无统计学意义(P>0.05)。结论硝苯地平控释片与缬沙坦联合治疗2型糖尿病肾病并高血压效果显著,适于临床推广及应用。

Objective To investigate the effect of nifedipine controlled-release tablets combined with valsartan in patients with type 2 diabetic nephropathy and hypertension and the effect on serum cystostatin C(CysC)and homocysteine(Hcy)influences.Methods The 98 study subjects were all patients with diabetic nephropathy and hypertension admitted to the hospital from December 2019 to November 2020.They were divided into two groups using a random number table method.Both groups of patients received conventional hypoglycemic therapy,and strictly followed a diabetic diet and exercised reasonably.The control group took nifedipine controlled-release tablets orally,and the study group took valsartan capsules orally on this basis.The blood glucose[fasting blood glucose(FPG),2 h blood glucose(2 hPG)after meal,glycosylated hemoglobin(HbA1c)],blood pressure[systolic blood pressure(SBP)and diastolic blood pressure(DBP)],renal function[serum creatinine(SCr)urea nitrogen(BUN),24 h urinary protein excretion rate(UAER)],CysC and Hcy levels,and adverse reactions were compared before and after treatment between the two groups.Results After treatment,the blood glucose(FPG,2 hPG,HbA1c)and blood pressure(SBP,DBP)levels of the study group were lower than those of the control group,the difference was statistically significant(P<0.05),and the levels of SCr,BUN,and UAER were lower than those of the control group,the difference was statistically significant(P<0.05),CysC and Hcy levels were lower than those of the control group,the difference was statistically significant(P<0.05).In the comparison of the incidence of adverse reactions between the two groups,there was no statistically significant difference between 4.08%of the study group and 4.08%of the control group(P>0.05).Conclusion The combination of nifedipine controlled-release tablets and valsartan has a significant effect in the treatment of type 2 diabetic nephropathy and hypertension,which is suitable for clinical promotion and application.